Skip to main content

Admera Health PGxOnco and LiquidGx Tests

Admera Health has launched two new tests: PGxOnco for cancer supportive care, and LiquidGx, a suite of liquid biopsy-based tests for tumor profiling and drug resistance monitoring. The PGxOnco test includes 50 genes and about 200 variants, and provides recommendations for over 300 drugs via next-generation sequencing. LiquidGx represents a menu of both qPCR and a NGS tests that analyze tumor DNA in blood samples. PCR assays allows for the genotyping of ALK, BRAF, EGFR, and KRAS either individually or together. The NGS panel, aimed specifically at lung cancer, includes AKT1, BRAF, ERBB2, MET, RET, ALK, EGFR, KRAS, PIK3CA,and ROS1.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.